Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 6/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038199 | 1.00 | CFTR (0.42) | CFTRACKR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2609426 | 0.88 | CFTR (0.43) | CFTRACKR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20162673 | 0.85 | CFTR (0.42) | CFTRACKR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30036854 | 0.85 | CFTR (0.42) | CFTRACKR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30038031 | 0.85 | CFTR (0.42) | CFTRACKR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20162691 | 0.85 | CFTR (0.42) | CFTRACKR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23283664 | 0.83 | CFTR (0.43) | CFTRACKR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20282471 | 0.83 | CFTR (0.43) | CFTRACKR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14947692 | 0.82 | GRM4 (0.43) | CFTR | |
| SCHEMBL30038045 | 0.79 | CFTR (0.44) | CFTRACKR3CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| CN-115850268-A | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会 | 2023-03-28 | — | — | CN | disclosed |
| CN-110337294-B | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会 | 2022-11-01 | — | — | CN | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| CN-110337294-A | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会治疗公司 | 2019-10-15 | — | — | CN | disclosed |
| EP-3541390-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation Therapeutics Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | CFTR 1/4885ACKR3 492/4885CYP1A2 1470/4885 |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | CFTR 1/4885ACKR3 492/4885CYP1A2 1470/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | CFTR 1/4885ACKR3 492/4885CYP1A2 1470/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | CFTR 1/4885ACKR3 361/4885CYP1A2 2350/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | CFTR 1/4885ACKR3 476/4885CYP1A2 1543/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | CFTR 1/4885ACKR3 476/4885CYP1A2 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.